JP2019509253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509253A5 JP2019509253A5 JP2018532746A JP2018532746A JP2019509253A5 JP 2019509253 A5 JP2019509253 A5 JP 2019509253A5 JP 2018532746 A JP2018532746 A JP 2018532746A JP 2018532746 A JP2018532746 A JP 2018532746A JP 2019509253 A5 JP2019509253 A5 JP 2019509253A5
- Authority
- JP
- Japan
- Prior art keywords
- phosphate
- alaninyl
- benzoxy
- gemcitabine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/054158 WO2017109444A1 (en) | 2015-12-23 | 2015-12-23 | Combination therapy |
| GBPCT/GB2015/054158 | 2015-12-23 | ||
| GB1609770.1 | 2016-06-03 | ||
| GBGB1609770.1A GB201609770D0 (en) | 2016-06-03 | 2016-06-03 | Combination therapy |
| PCT/GB2016/054018 WO2017109486A1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509253A JP2019509253A (ja) | 2019-04-04 |
| JP2019509253A5 true JP2019509253A5 (enExample) | 2020-01-09 |
| JP6898329B2 JP6898329B2 (ja) | 2021-07-07 |
Family
ID=57681677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532746A Expired - Fee Related JP6898329B2 (ja) | 2015-12-23 | 2016-12-21 | 併用療法 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20190022117A1 (enExample) |
| EP (2) | EP3393478B1 (enExample) |
| JP (1) | JP6898329B2 (enExample) |
| KR (1) | KR20180096698A (enExample) |
| CN (1) | CN108697725A (enExample) |
| AU (1) | AU2016375861B2 (enExample) |
| CA (1) | CA3008749C (enExample) |
| CY (1) | CY1122835T1 (enExample) |
| DK (1) | DK3393478T3 (enExample) |
| EA (1) | EA037459B1 (enExample) |
| ES (1) | ES2778933T3 (enExample) |
| HR (1) | HRP20200423T1 (enExample) |
| HU (1) | HUE050290T2 (enExample) |
| IL (1) | IL260076A (enExample) |
| LT (1) | LT3393478T (enExample) |
| MA (1) | MA51576A (enExample) |
| MD (1) | MD3393478T2 (enExample) |
| ME (1) | ME03677B (enExample) |
| MX (1) | MX383988B (enExample) |
| MY (1) | MY194629A (enExample) |
| PH (1) | PH12018501339A1 (enExample) |
| PL (1) | PL3393478T3 (enExample) |
| PT (1) | PT3393478T (enExample) |
| RS (1) | RS60211B1 (enExample) |
| SG (1) | SG11201805184TA (enExample) |
| SI (1) | SI3393478T1 (enExample) |
| SM (1) | SMT202000154T1 (enExample) |
| WO (1) | WO2017109486A1 (enExample) |
| ZA (1) | ZA201804155B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2725491T3 (es) | 2012-11-16 | 2019-09-24 | Univ College Cardiff Consultants Ltd | Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato |
| RS60968B1 (sr) | 2014-06-25 | 2020-11-30 | NuCana plc | Prolekovi gemcitabina |
| PT3119794T (pt) | 2014-06-25 | 2018-01-15 | Nucana Biomed Ltd | Formulação que compreende um pró-fármaco de gemcitabina |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| CA2994502C (en) | 2015-10-05 | 2023-08-01 | NuCana plc | Combination therapy comprising nuc-1031 and carboplatin for cancer treatment |
| KR20180101370A (ko) | 2015-12-11 | 2018-09-12 | 뉴카나 피엘씨 | 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| JP2015524467A (ja) * | 2012-08-13 | 2015-08-24 | レギュロン、インク.Regulon, Inc. | Ｌｉｐｏｐｌａｔｉｎを使用するがんの処置方法 |
| CA2891124A1 (en) * | 2012-11-13 | 2014-05-22 | BoYen Therapeutics, Inc. | Gemcitabine prodrugs and uses thereof |
| CA2985540C (en) * | 2015-05-14 | 2021-08-24 | NuCana plc | Use of nuc-1031 in the treatment of cancer |
| CA2994502C (en) * | 2015-10-05 | 2023-08-01 | NuCana plc | Combination therapy comprising nuc-1031 and carboplatin for cancer treatment |
-
2016
- 2016-12-21 EP EP16820005.3A patent/EP3393478B1/en active Active
- 2016-12-21 MD MDE20181039T patent/MD3393478T2/ro not_active IP Right Cessation
- 2016-12-21 CN CN201680082464.9A patent/CN108697725A/zh active Pending
- 2016-12-21 WO PCT/GB2016/054018 patent/WO2017109486A1/en not_active Ceased
- 2016-12-21 ME MEP-2020-56A patent/ME03677B/me unknown
- 2016-12-21 US US16/065,498 patent/US20190022117A1/en not_active Abandoned
- 2016-12-21 EP EP20160070.7A patent/EP3738595A1/en not_active Withdrawn
- 2016-12-21 HR HRP20200423TT patent/HRP20200423T1/hr unknown
- 2016-12-21 SI SI201630680T patent/SI3393478T1/sl unknown
- 2016-12-21 MY MYPI2018001015A patent/MY194629A/en unknown
- 2016-12-21 SG SG11201805184TA patent/SG11201805184TA/en unknown
- 2016-12-21 LT LTEP16820005.3T patent/LT3393478T/lt unknown
- 2016-12-21 MA MA051576A patent/MA51576A/fr unknown
- 2016-12-21 HU HUE16820005A patent/HUE050290T2/hu unknown
- 2016-12-21 PL PL16820005T patent/PL3393478T3/pl unknown
- 2016-12-21 RS RS20200297A patent/RS60211B1/sr unknown
- 2016-12-21 ES ES16820005T patent/ES2778933T3/es active Active
- 2016-12-21 EA EA201891473A patent/EA037459B1/ru unknown
- 2016-12-21 DK DK16820005.3T patent/DK3393478T3/da active
- 2016-12-21 MX MX2018007772A patent/MX383988B/es unknown
- 2016-12-21 PT PT168200053T patent/PT3393478T/pt unknown
- 2016-12-21 AU AU2016375861A patent/AU2016375861B2/en not_active Ceased
- 2016-12-21 CA CA3008749A patent/CA3008749C/en active Active
- 2016-12-21 KR KR1020187020533A patent/KR20180096698A/ko not_active Ceased
- 2016-12-21 SM SM20200154T patent/SMT202000154T1/it unknown
- 2016-12-21 JP JP2018532746A patent/JP6898329B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-17 IL IL260076A patent/IL260076A/en unknown
- 2018-06-21 ZA ZA2018/04155A patent/ZA201804155B/en unknown
- 2018-06-21 PH PH12018501339A patent/PH12018501339A1/en unknown
-
2020
- 2020-03-17 CY CY20201100245T patent/CY1122835T1/el unknown
-
2022
- 2022-06-21 US US17/845,878 patent/US20230149436A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509253A5 (enExample) | ||
| RU2767664C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| Monneret | Platinum anticancer drugs. From serendipity to rational design | |
| US20180256578A1 (en) | A Combination Therapy Comprising Varlitinib and an Anticancer Agent | |
| Chae et al. | Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit? | |
| JP2020535173A5 (enExample) | ||
| JP2012521435A5 (enExample) | ||
| HRP20200423T1 (hr) | Kombinirana terapija | |
| JP2012506448A5 (enExample) | ||
| JP7193591B2 (ja) | 化学療法の改善 | |
| JP2014533277A5 (enExample) | ||
| JP2020523356A5 (enExample) | ||
| BR112012030641B1 (pt) | Usos e composições para terapia farmacêutica oral | |
| CN102056609B (zh) | 药物组合 | |
| BR112021007283A2 (pt) | método de tratamento de um câncer ou câncer refratário | |
| JP2021505669A5 (enExample) | ||
| ES2389809T3 (es) | Terapias anticancerosas | |
| ES3027841T3 (en) | Miv-818/lenvatinib combination therapy for liver cancer | |
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| WO2021048417A1 (en) | Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma | |
| BR112019019491A2 (pt) | sulfoximina butionina e um metalofármaco para tratamento de câncer, hiv ou uma doença reumática | |
| JPWO2021260111A5 (enExample) | ||
| JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP7822619B2 (ja) | 胆管癌の処置のためのパノビノスタットを含む併用療法 | |
| WO2021048419A1 (en) | Combination therapies comprising trametinib for the treatment of cholangiocarcinoma |